Tirzepatide

About

Tirzepatide, also known as LY3298176, is a 39-amino-acid synthetic peptide based on the human GIP hormone that acts as a dual agonist of the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. A C20 fatty di-acid moiety extends its duration of action and supports once-weekly dosing. Research has explored its effects on insulin response, appetite, glycemic control, and body weight, often in comparison with GLP-1-only agonists. It was approved by the FDA in May 2022 (Mounjaro) for type 2 diabetes and later for chronic weight management (Zepbound).

Research Applications

• Weight loss
• Glycemic control
• Lipid profile
• Type 2 diabetes

Mechanism of Action

The research literature describes tirzepatide as mimicking endogenous GIP while stimulating cAMP synthesis at the GLP-1 receptor, producing a synergistic effect with enhanced glucose-dependent insulin response and glucagonostatic activity relative to GIP or GLP-1 agonism alone.

Molecular Info

Class

Peptide

Length

39 amino acids

Structure

GIP-based dual agonist with a C20 fatty di-acid moiety for extended duration

Primary research areas

Glycemic control, weight management, and lipid profile

Dosing Guidance

Range

Clinical references describe once-weekly dosing escalated over time, with research references commonly citing 2.5 mg up to 15 mg weekly depending on the protocol and population studied.

Frequency

Once weekly in the clinical literature, typically with gradual dose escalation.

Timing

Timing is not consistently defined across the available research references.

Cycle length

Cycle length is not consistently defined across the available research references.

Notes

These details are educational context only. Protocol values are examples and should not be treated as medical instructions.

Known Risks

• Gastrointestinal side effects reported in clinical studies
• Hypersensitivity reactions
• Thyroid C-cell tumors observed in rodent studies

Regulatory & Evidence Status

Evidence level

Supported by completed clinical trials; long-term outcomes still being characterized.

FDA status

Approved — type 2 diabetes (Mounjaro, 2022) and chronic weight management (Zepbound).

Availability

Prescription medication.